biomarkers for acute myeloid leukemia (aml) – lessons from il-2 immunotherapy with hdc
Published 7 years ago • 558 plays • Length 6:18Download video MP4
Download video MP3
Similar videos
-
2:01
predict response to immune checkpoint inhibition in acute myeloid leukemia (aml) using biomarkers
-
1:44
new targets to treat acute myeloid leukemia (aml) with flt3 mutations
-
1:17
remission maintenance with histamine dihydrochloride (hdc)/il-2 therapy in aml
-
4:58
the molecular heterogeneity of acute myeloid leukemia (aml) – new data and implications
-
1:32
the importance of cytogenetics and molecular profiling for accurate aml/mds diagnosis
-
4:34
the genetics of acute myeloid leukemia (aml)
-
1:08:41
immunophenotyping of acute leukemia - part 2 of 4
-
6:39
treatment failure and relapse in acute myeloid leukemia (aml)
-
2:33
novel immunotherapies in aml and insights into the future of the treatment landscape
-
3:00
the classification of aml and the role of genetic biomarkers in the management of aml
-
1:39
results of the german acute myeloid leukemia (aml) intergroup study
-
2:00
an overview of immunotherapies for leukemia
-
1:02
maintenance therapy following treatment for amyloidosis
-
1:48
treatment options for patients with aml that are not candidates for intensive chemotherapy
-
1:44
serum neurofilament light chain as an early disease biomarker in attr amyloidosis
-
2:29
the measurement of molecular biomarkers to aid cll treatment
-
2:25
advances in acute myeloid leukemia (aml) treatment – updating 7 3
-
3:37
biomarker analysis of luspatercept versus epoetin alfa in lr-mds in the phase iii commands study
-
1:12
using biomarkers and genomics to inform treatment strategy in all
-
1:58
potential biomarkers of pembrolizumab response after hidac in r/r aml
-
2:48
key targets and the future of immunotherapy in aml